• Mineralys Therapeutics presented Transform-HTN results November 8, 2026, showing sustained blood pressure reductions with lorundrostat in uncontrolled or resistant hypertension.
• Blood pressure reductions persisted for nearly a year, with more than half of participants reaching the recommended systolic blood pressure target.
• Long-term treatment was well tolerated, with no new clinically relevant safety findings compared with Launch-HTN.
• FDA review of lorundrostat as an add-on hypertension treatment is underway, with a decision target date of December 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081635PRIMZONEFULLFEED9872602) on November 08, 2026, and is solely responsible for the information contained therein.